SCHEMBL2233829

SCHEMBL2233829

CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OCCCC[C@@H](O)CO

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.67
▸ AKT1 P31749 2/20 0.67
▸ LMNA P02545 2/20 0.67
▸ ALDH1A1 P00352 2/20 0.67
▸ PRKD3 O94806 1/20 0.67
▸ PRKCG P05129 1/20 0.67
▸ PRKCB P05771 1/20 0.67
▸ PRKCA P17252 1/20 0.67
▸ PRKCH P24723 1/20 0.67
▸ PRKCI P41743 1/20 0.67
▸ PRKCE Q02156 1/20 0.67
▸ PRKCQ Q04759 1/20 0.67
▸ PRKCZ Q05513 1/20 0.67
▸ PRKCD Q05655 1/20 0.67
▸ PRKD1 Q15139 1/20 0.67
▸ MAPK1 P28482 1/20 0.67
▸ MEN1 O00255 1/20 0.67
▸ GMNN O75496 1/20 0.67
▸ BLM P54132 1/20 0.67
▸ KMT2A Q03164 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL417053 0.89 AKT1 (0.83) SMN1; SMN2AKT1LMNAALDH1A1PRKD3
SCHEMBL2733343 0.89 AKT1 (0.83) SMN1; SMN2AKT1LMNAALDH1A1PRKD3
SCHEMBL2582886 0.89 AKT1 (0.83) SMN1; SMN2AKT1LMNAALDH1A1PRKD3
SCHEMBL15477735 0.89 AKT1 (0.83) SMN1; SMN2AKT1LMNAALDH1A1PRKD3
SCHEMBL10564175 0.89 AKT1 (0.83) SMN1; SMN2AKT1LMNAALDH1A1PRKD3
SCHEMBL10602960 0.89 AKT1 (0.83) SMN1; SMN2AKT1LMNAALDH1A1PRKD3
SCHEMBL10565337 0.89 AKT1 (0.83) SMN1; SMN2AKT1LMNAALDH1A1PRKD3
SCHEMBL2734265 0.89 AKT1 (0.83) SMN1; SMN2AKT1LMNAALDH1A1PRKD3
SCHEMBL11035217 0.89 AKT1 (0.83) SMN1; SMN2AKT1LMNAALDH1A1PRKD3
SCHEMBL1532761 0.89 AKT1 (0.83) SMN1; SMN2AKT1LMNAALDH1A1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206206-B2 Oxidized lipid compounds and uses thereof VASCULAR BIOGENICS LTD. (IL) 2015-12-08 — — US disclosed
EP-2826369-A2 Oxidized lipid compounds and uses thereof Vascular Biogenics Ltd. (IL) 2015-01-21 — — EP disclosed
EP-2826370-A2 Oxidized lipid compounds and uses thereof Vascular Biogenics Ltd. (IL) 2015-01-21 — — EP disclosed
EP-2348866-B1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD (IL) 2015-01-07 — — EP disclosed
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof VASCULAR BIOGENICS LTD. (IL) 2013-08-08 — — US disclosed
CN-102271517-A oxidized lipid compounds and uses thereof — 2011-12-07 — — CN disclosed
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2011-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof LPO, GPX4, ALOX15B SMN1; SMN2 4440/4885AKT1 4087/4885LMNA 2239/4885
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF LPO, GPX4, ALOX15B SMN1; SMN2 4440/4885AKT1 4087/4885LMNA 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback